Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2023-10-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于使用非公开发行部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the use of idle funds raised from a non-public stock issuance to temporarily supplement working capital. It details the approval by the board, the amount and purpose of the funds, compliance with regulatory requirements, and opinions from independent directors, the supervisory board, and the sponsoring institution. The document does not contain financial statements or detailed financial performance data but rather focuses on the use of funds and compliance with regulations. It is a regulatory announcement about capital usage and financing activities, specifically about the temporary use of idle raised funds to supplement working capital. This fits the definition of a Capital/Financing Update (CAP). The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it is itself the announcement of a financing-related decision. Therefore, the appropriate classification is CAP with high confidence.
2023-10-26 Chinese
独立董事关于相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from independent directors regarding the use of idle raised funds to temporarily supplement working capital. It references compliance with laws and regulations and provides an opinion on a specific financial management matter. The document is short (794 characters) and does not contain financial statements or detailed financial data. It is not a full report but an opinion related to a specific corporate governance or regulatory compliance issue. This fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2023-10-26 Chinese
东莞证券关于特一药业使用非公开发行部分闲置募集资金暂时补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from Dongguan Securities regarding the use of idle raised funds from a non-public stock issuance by Te Yi Pharmaceutical Group Co., Ltd. It discusses the approval, usage, and compliance of temporarily supplementing working capital with idle raised funds. The document references regulatory guidelines and approvals, and includes opinions from the board, independent directors, supervisors, and the sponsor institution. It is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a regulatory compliance and verification report related to capital usage and fundraising activities. This fits best under Capital/Financing Update (CAP) as it concerns the use and management of raised capital funds and related approvals.
2023-10-26 Chinese
关于第五届董事会第十五次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board of directors meeting resolution by 特一药业集团股份有限公司. It details the meeting date, attendance, and the resolution passed regarding the use of idle raised funds to temporarily supplement working capital. The document is short (967 characters) and serves as a formal announcement of a board decision rather than a full report or financial statement. It does not contain financial statements or detailed management discussion. The content fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. Therefore, the appropriate classification is MANG with high confidence.
2023-10-26 Chinese
关于第五届监事会第十四次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of a resolution passed at the 14th meeting of the 5th Supervisory Board of the company. It details the approval of a proposal regarding the temporary use of idle raised funds to supplement working capital. The document includes meeting attendance, voting results, and compliance with company laws and articles. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is a formal announcement of a board/management decision related to fund usage. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Hence, classification as MANG is appropriate with high confidence.
2023-10-26 Chinese
关于特一转债到期的第一次提示性公告
Delisting Announcement Classification · 95% confidence The document is an announcement regarding the stopping of trading and maturity of a convertible bond ("特一转债") issued by the company. It details the stop trading date, conversion period, redemption price, and the subsequent delisting of the bond from the Shenzhen Stock Exchange. There are no financial statements or detailed financial performance data presented. The document serves as a formal notification about the bond's maturity, trading cessation, and redemption process, which aligns with a Delisting Announcement rather than a full financial report or other categories.
2023-10-25 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.